Treatment and evaluation of CLL: A complicated affair

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In this issue, Eichhorst and colleagues show in a large randomized phase 3 clinical trial that combination therapy using fludarabine and cyclophosphamide is superior to fludarabine alone for younger previously untreated CLL patients. In addition, they found a reduced level of clinical responses when imaging was considered as part of restaging compared with responses defined by recommended NCI standards.

Original languageEnglish (US)
Pages (from-to)848
Number of pages1
JournalBlood
Volume107
Issue number3
DOIs
StatePublished - Feb 1 2006

Fingerprint

Phase III Clinical Trials
Cyclophosphamide
Randomized Controlled Trials
Imaging techniques
Therapeutics
fludarabine

ASJC Scopus subject areas

  • Hematology

Cite this

Treatment and evaluation of CLL : A complicated affair. / Kay, Neil Elliot.

In: Blood, Vol. 107, No. 3, 01.02.2006, p. 848.

Research output: Contribution to journalArticle

@article{47cbe64b8a1444f083644805f6174d4d,
title = "Treatment and evaluation of CLL: A complicated affair",
abstract = "In this issue, Eichhorst and colleagues show in a large randomized phase 3 clinical trial that combination therapy using fludarabine and cyclophosphamide is superior to fludarabine alone for younger previously untreated CLL patients. In addition, they found a reduced level of clinical responses when imaging was considered as part of restaging compared with responses defined by recommended NCI standards.",
author = "Kay, {Neil Elliot}",
year = "2006",
month = "2",
day = "1",
doi = "10.1182/blood-2005-11-4501",
language = "English (US)",
volume = "107",
pages = "848",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Treatment and evaluation of CLL

T2 - A complicated affair

AU - Kay, Neil Elliot

PY - 2006/2/1

Y1 - 2006/2/1

N2 - In this issue, Eichhorst and colleagues show in a large randomized phase 3 clinical trial that combination therapy using fludarabine and cyclophosphamide is superior to fludarabine alone for younger previously untreated CLL patients. In addition, they found a reduced level of clinical responses when imaging was considered as part of restaging compared with responses defined by recommended NCI standards.

AB - In this issue, Eichhorst and colleagues show in a large randomized phase 3 clinical trial that combination therapy using fludarabine and cyclophosphamide is superior to fludarabine alone for younger previously untreated CLL patients. In addition, they found a reduced level of clinical responses when imaging was considered as part of restaging compared with responses defined by recommended NCI standards.

UR - http://www.scopus.com/inward/record.url?scp=31544433388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31544433388&partnerID=8YFLogxK

U2 - 10.1182/blood-2005-11-4501

DO - 10.1182/blood-2005-11-4501

M3 - Article

AN - SCOPUS:31544433388

VL - 107

SP - 848

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -